Authors
Géraldine M Camilleri, Eléa Janvier, Frédéric Pigneur, Joris Mallard, Philippe Marijnen, Pauline Vidican, Mirianna Mouret-Bonzi, Eva Esther Molina Beltran, Océane Cotard, Bruno Raynard, Cindy Neuzillet
Published in
Bulletin du cancer. Sep 17, 2026. Epub Sep 17, 2026.
Abstract
Sarcopenia is defined as a loss of muscle mass and strength. It represents a frequent and multifactorial complication in patients with gastrointestinal cancers, resulting from the combined effects of malnutrition, chronic inflammation, metabolic alterations, and reduced physical activity level. Its assessment relies on a combined approach integrating imaging tools and functional tests. Computed tomography, widely available in oncology, represents the reference method for the evaluation of body composition, particularly skeletal muscle mass and quality. Functional tests allow assessment of muscle strength and physical performance. Sarcopenia, including sarcopenic obesity phenotype, has a major prognostic impact from localized disease to advanced stages, being associated with an increased risk of postoperative complications, reduced tolerance to anticancer treatments, and decreased survival. Its management should be early, personalized, and multimodal, combining nutritional support, adapted physical activity, and a global patient-centered approach. Prehabilitation programs illustrate the benefits of an integrated strategy, whereas pharmacological approaches remain limited to date. Thus, sarcopenia should be considered an essential component of the care pathway in gastrointestinal oncology.
PMID:
42754415
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0